ARIAD Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals

ARIA 23.99

0.0%

Feb 17 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Boyce Burge who wrote (266)	3/23/1998 6:48:00 AM
From: SnowShredder	Read Replies (1) of 4474

The inutero gene therapy is a good way of overcoming the current deficiency in the vectors available today. Retroviral vectors have titers that are too low for effective invivo gene therapy. Thus if you in infect a fetus the number of cells to be infected are reduced dramatically, as well as cell division being very active...allowing integration of DNA. Ariad will have competition for being the pioneer in this type of therapy...French Anderson said @ UCLA that he was very interested in being a pioneer in this therapy. I also agree with you that it will be a while before they will be able to collect on this technology. Best of luck, Where'd He Go?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next